Psoraxine™ - Astralis
Novel injectable psoriasis vaccine therapy
Psoriasis
- Under-treated (only 1 in 4 US sufferers)
- Affects 3% world’s population (14 million US/Europe)
- Total market size US$2bn (JP Morgan/Goldman Sachs)
- Current treatments: limited efficacy, potential side effects
Venezuelan clinical studies
- 638 (28%) of 3000 patients achieved complete remission
- 46% experienced 70-99% disease reduction (PASI score)
US$16m for technology access and service agreements: SKP to carry out all development
SKP investing up to US$20 m over next year